financetom
Business
financetom
/
Business
/
B2Gold Announces Menankoto Exploitation Permit Granted by Mali Government; Shares Jump 23%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
B2Gold Announces Menankoto Exploitation Permit Granted by Mali Government; Shares Jump 23%
Aug 7, 2026 10:54 AM

01:36 PM EDT, 08/07/2026 (MT Newswires) -- B2Gold ( BTG ) has been granted an exploitation permit for its Menankoto project in Mali, the company said on Friday.

Its shares surged 23% to C$7.04, the highest since May 14, on the Toronto Stock Exchange.

The newest permit, together with the Dandoko exploration permit, make up Fekola Regional, which is a key near-term production growth driver for B2Gold ( BTG ), a statement said. B2Gold ( BTG ) said it had been in talks with the Mali government since July 2025.

The Fekola Complex consists of the Fekola Mine, owned 80% by B2Gold ( BTG ) and 20% by Mali, and Fekola Regional (Menankoto exploitation Permit and Dandoko permit), which will be owned 65% by B2Gold ( BTG ) and 35% by the state of Mali.

With the Menankoto permit in hand, mining pre-stripping activities and finalization of a tolling agreement will begin. Fekola Regional is expected to ramp up operations through the end of 2027 and produce in excess of 150,000 ounces per year from 2028 through the mid-2030's.

B2 Gold late Thursday reported second-quarter adjusted earnings down to $0.03 per share, from $0.12 per share for the prior year period.

Analysts polled by FactSet had expected adjusted earnings of $0.07 per share.

B2Gold ( BTG ) narrowed its gold production guidance to between 820,000 and 920,000 ounces, from the previous 820,000 and 970,000 ounces.

The company will pay a quarterly cash dividend of $0.02 per share, on Sept. 23, to shareholders of record on Sept. 10.

Price: 6.96, Change: +1.22, Percent Change: +21.25

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Restaurant Brands Q2 Mixed as Burger King Strength Offsets Tim Hortons, Popeyes Weakness, RBC Says
Restaurant Brands Q2 Mixed as Burger King Strength Offsets Tim Hortons, Popeyes Weakness, RBC Says
Aug 7, 2026
01:33 PM EDT, 08/07/2026 (MT Newswires) -- Restaurant Brands International (QSR) reported mixed Q2 results, with strong performances from Burger King and its international business offset by weaker-than-expected results at Tim Hortons and Popeyes, RBC Capital Markets said. The investment firm said in a Thursday note that Burger King and international same-store sales topped consensus estimates. Tim Hortons same-store sales...
Georgia AG Launches Probe Into Roblox, Social Media Platforms
Georgia AG Launches Probe Into Roblox, Social Media Platforms
Aug 7, 2026
01:35 PM EDT, 08/07/2026 (MT Newswires) -- Georgia Attorney General Chris Carr said Friday on X his office is launching investigations into Roblox ( RBLX ) and social media platforms over child safety concerns. Roblox ( RBLX ) is a playground for predators, and social media platforms aren't any better, Carr said on X. Big tech refuses to step up...
B2Gold Announces Menankoto Exploitation Permit Granted by Mali Government; Shares Jump 23%
B2Gold Announces Menankoto Exploitation Permit Granted by Mali Government; Shares Jump 23%
Aug 7, 2026
01:36 PM EDT, 08/07/2026 (MT Newswires) -- B2Gold ( BTG ) has been granted an exploitation permit for its Menankoto project in Mali, the company said on Friday. Its shares surged 23% to C$7.04, the highest since May 14, on the Toronto Stock Exchange. The newest permit, together with the Dandoko exploration permit, make up Fekola Regional, which is a...
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says
Aug 7, 2026
01:36 PM EDT, 08/07/2026 (MT Newswires) -- Regenxbio's ( RGNX ) Duchenne muscular dystrophy gene therapy appears approvable, with efficacy comparable to Sarepta Therapeutics (SRPT) and a more favorable safety profile, as the company moves toward submitting its rolling biologics license application, RBC Capital Markets said Thursday in a report. Regenxbio ( RGNX ) is on track to file the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved